K
KINIKSA PHARMACEUTICALS LTD
NASDAQ: KNSA (Kiniksa Pharmaceuticals Interna)
Kemas kini terakhir: 3 jam lalu55.27
1.49 (2.77%)
| Penutupan Terdahulu | 53.78 |
| Buka | 53.78 |
| Jumlah Dagangan | 854,206 |
| Purata Dagangan (3B) | 713,252 |
| Modal Pasaran | 4,252,364,288 |
| Harga / Pendapatan (P/E TTM) | 60.74 |
| Harga / Pendapatan (P/E Ke hadapan) | 59.52 |
| Harga / Jualan (P/S) | 5.47 |
| Harga / Buku (P/B) | 6.31 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Jul 2026 |
| Margin Keuntungan | -3.52% |
| Margin Operasi (TTM) | 9.63% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 72.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 3.66 |
| Aliran Tunai Operasi (OCF TTM) | 44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.15 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Kiniksa Pharmaceuticals Interna | Menaik | Menaik |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.63 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.80% |
| % Dimiliki oleh Institusi | 97.31% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rubric Capital Management Lp | 31 Dec 2025 | 3,328,653 |
| Baker Bros. Advisors Lp | 31 Dec 2025 | 2,826,246 |
| Tang Capital Management Llc | 31 Dec 2025 | 2,259,889 |
| Acadian Asset Management Llc | 31 Dec 2025 | 1,713,043 |
| Fairmount Funds Management Llc | 31 Dec 2025 | 1,319,688 |
| Arrowstreet Capital, Limited Partnership | 31 Dec 2025 | 1,068,216 |
| Millennium Management Llc | 31 Dec 2025 | 825,285 |
| Point72 Asset Management, L.P. | 31 Dec 2025 | 797,137 |
| Qube Research & Technologies Ltd | 31 Dec 2025 | 766,291 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 62.00 (Canaccord Genuity, 12.18%) | Beli |
| Median | 53.00 (-4.11%) | |
| Rendah | 53.00 (Wedbush, -4.11%) | Beli |
| 53.00 (Wells Fargo, -4.11%) | Beli | |
| Purata | 56.00 (1.32%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 44.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 25 Feb 2026 | 53.00 (-4.11%) | Beli | 42.76 |
| Wells Fargo | 25 Feb 2026 | 53.00 (-4.11%) | Beli | 42.76 |
| Canaccord Genuity | 19 Feb 2026 | 62.00 (12.18%) | Beli | 47.17 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |